TEVA vs. VTRS: Teva Pharmaceutical vs. Viatris Stock Comparison
How do Teva Pharmaceutical (TEVA) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Teva Pharmaceutical (TEVA) and Viatris (VTRS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Viatris (VTRS) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | TEVA | VTRS |
|---|---|---|
| Name | Teva Pharmaceutical Industries Ltd. ADR | Viatris Inc. |
| Country/Region | Israel | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 49.72 billion USD | 22.83 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 16, 1982 | March 17, 1980 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| Total Return (1Y) | 79.58% | 108.98% |
| Total Return (3Y, Annualized) | 69.94% | 36.75% |
| Total Return (5Y, Annualized) | 35.86% | 11.59% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| Volatility (1Y, Annualized) | 33.95% | 32.53% |
| Beta (5Y) | 0.96 | 0.86 |
| Max Drawdown (5Y) | -43.70% | -45.69% |
| Avg. Volume (3M) | 5.91M | 8.87M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| Sharpe Ratio (1Y) | 2.22 | 3.22 |
| Sortino Ratio (1Y) | 3.94 | 5.63 |
Profitability
ROE (TTM)
Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Teva Pharmaceutical (TEVA) reports 6.65%, ranking against industry peers normally.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.65%
- Max
- 109.18%
- TEVA
- 6.65%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.21%
- Max
- 109.18%
- Q3
- 6.23%
- VTRS
- -4.21%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Teva Pharmaceutical (TEVA) reports 2.94%, ranking against industry peers normally.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94%
- Max
- 18.05%
- Q3
- 4.78%
- TEVA
- 2.94%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.13%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- VTRS
- -4.13%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Teva Pharmaceutical (TEVA) at 27.40% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.40%
- Max
- 83.12%
- TEVA
- 27.40%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.85%
- Max
- 83.12%
- Q3
- 14.77%
- VTRS
- 13.85%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| ROE (TTM) | 6.65% | -4.21% |
| ROA (TTM) | 5.35% | 2.91% |
| Net Margin (TTM) | 2.94% | -4.13% |
| Operating Margin (TTM) | 27.40% | 13.85% |
| Gross Margin (TTM) | 53.51% | 41.13% |
Growth
Revenue Growth
Teva Pharmaceutical (TEVA) at 4.31% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Neither Teva Pharmaceutical (TEVA) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| Revenue Growth (YoY) | 4.31% | -2.98% |
| Revenue Growth (3Y CAGR) | 4.96% | -4.20% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Teva Pharmaceutical (TEVA) at 0.95 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TEVA
- 0.95
- Min
- 0.10
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VTRS
- 1.55
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Viatris (VTRS) at 0.99 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.13
- TEVA
- 2.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.99
- Max
- 1.42
- VTRS
- 0.99
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 0.95 | 1.55 |
| Debt / Equity (MRQ) | 2.13 | 0.99 |
| Net Debt / EBITDA | 2.93 | 2.64 |
Dividends
Dividend Yield (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.53%
- VTRS
- 2.53%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%).
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
960.00%
- VTRS
- 960.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.53% |
| Dividend Payout Ratio (TTM) | 0.00% | 960.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Teva Pharmaceutical (TEVA) trades at 99.09 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
99.09
- TEVA
- 99.09
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- VTRS
- --
P/S Ratio (TTM)
Both Teva Pharmaceutical (TEVA) at 2.89 and Viatris (VTRS) at 1.55 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.89
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- TEVA
- 2.89
- Min
- 0.01
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- VTRS
- 1.55
- Min
- 0.01
P/B Ratio (MRQ)
Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Teva Pharmaceutical (TEVA) at 6.23 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.23
- Max
- 13.53
- Q3
- 6.54
- TEVA
- 6.23
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- VTRS
- 1.67
- Min
- -5.59
Valuation Metrics
| Metric | TEVA | VTRS |
|---|---|---|
| P/E Ratio (TTM) | 99.09 | -- |
| P/S Ratio (TTM) | 2.89 | 1.55 |
| P/B Ratio (MRQ) | 6.23 | 1.67 |
| Free Cash Flow Yield (TTM) | 3.00% | 13.84% |